ResMed has secured FDA clearance for its Personalized Therapy Comfort Settings (PTCS), branded as Smart Comfort, marking a significant step in AI-driven sleep apnea treatment. The clearance could boost market confidence in the company’s technological leadership.
ResMed Gains FDA Approval
In early trading on December 8, 2025, ResMed’s stock (RMD) traded at $252.75, a marginal decrease of 0.01481% from the previous day’s close. Intraday trading saw a high of $257.00 and a low of $252.21, with a trading volume of 114,477 shares. The market reaction has been muted, reflecting a wait-and-see approach.
Smart Comfort, the first FDA-cleared AI-enabled medical device of its kind, personalizes comfort settings for individuals undergoing CPAP therapy for obstructive sleep apnea (OSA). ResMed plans a limited U.S. beta launch in early 2026 for new users of the myAir app paired with AirSense 11 devices, followed by a broader rollout later that year. The system leverages machine learning algorithms and data from over 100 million nights of sleep to tailor therapy settings.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
Recent months have seen ResMed achieve several milestones. In October 2025, the company introduced the AirTouch F30i Comfort mask in Australia, which later received a Gold award at the Australian Good Design Awards. In March 2024, ResMed launched the AirFit F40, an ultra-compact full-face mask, demonstrating ongoing innovation in sleep therapy solutions. In August 2025, ResMed announced it had reached 10,000 patents and designs, with the AirTouch™ N30i nasal cradle mask winning two Red Dot Awards for Product Design 2025.
The company’s strategic initiatives and product innovations may contribute to a more optimistic long-term outlook. The FDA clearance for Smart Comfort positions ResMed at the forefront of integrating AI into sleep therapy, potentially boosting market confidence due to anticipated market expansion and technological leadership. The positive reception of products like the AirTouch F30i Comfort mask may enhance ResMed’s brand reputation and market share.
RMD Analyst Summary
Bull Case
- FDA clearance for Smart Comfort enhances technological leadership.
- Innovative product launches improve brand reputation and market share.
- Reaching 10,000 patents highlights commitment to innovation.
Bear Case
- Muted immediate market reaction suggests investor caution.
- Broader rollout of Smart Comfort is not expected until late 2026.
- Minimal stock price change reflects short-term uncertainty.
ResMed’s recent advancements and product launches signal a strong commitment to innovation in the sleep therapy market. While the immediate market reaction to the FDA clearance has been neutral, the company’s long-term growth prospects could be bolstered by these strategic developments.
